Baskies Arnold M

Director Baskies Arnold M bought 10,000 shares of ANIX at $3.04 on 2026-01-28 (8.0% stake increase to 135.0K shares).

Director Baskies Arnold M purchased 10,000 shares at $3.04, increasing his holdings to 135,000 shares, an 8.0% increase from pre-transaction levels. The current price of $3.10 is -40.6% from the 52-week high of $5.22 and down 24.9% over the past 90 days, placing the stock in a depressed position. His prior ANIX trades show mixed timing: two of three measurable outcomes showed positive 90-day returns (+29.8% and +1.9%), though one prior buy declined -25.1% over 90 days. The company remains unprofitable (net income of -$2.3M most recent quarter) with stalled revenue growth (0.0% annual growth), which constrains the fundamental backdrop for conviction assessment. This purchase follows his January 2025 buy at the same price point, but without additional context on transaction timing or agreement flags, the motivations remain opaque—only the price action relative to his recent history and the company's financial position are observable.

Director Baskies Arnold M buys 5,000 shares of ANIX at $3.39; part of 2-insider cluster buy in 14 days

Baskies Arnold M purchased 5,000 shares at $3.39 on 2025-07-18, increasing his holdings by 5,000 shares to 125,000 shares post-transaction. This buy occurs alongside a 2-other-insider cluster pattern within the past 14 days, suggesting coordinated director-level confidence. However, the company remains unprofitable with net income of $-2,790,000.00 against revenue of $210,000.00, and annual revenue growth is +0.0%, indicating financial headwinds. At the same ticker, the insider's prior buy on 2024-03-15 resulted in a 90-day return of -25.1%, and his cross-ticker track record shows a 90-day win rate of only 50.00%, suggesting mixed timing accuracy. The stock has risen 26.1% over 90 days but remains 13.6% below its 52-week high, leaving unclear whether this represents conviction in a turnaround or a continuation of inconsistent positioning.

Director Baskies Arnold M bought 5,000 ANIX shares at $2.82; 3 other insiders also bought in past 14 days.

Director Baskies Arnold M purchased 5,000 shares at $2.82, increasing his holdings to 120,000 shares. This transaction is part of a cluster pattern: 3 other insiders also bought within the past 14 days, suggesting coordinated or independent alignment on valuation at current levels. However, the company remains unprofitable with net income of $-3,277,000.00 in the latest quarter and zero annual revenue growth, while the stock is currently -35.3% from its 52-week high of $4.64. Arnold's prior two purchases at ANIX produced mixed results (30d returns of +2.9% and -12.7%, respectively), indicating inconsistent timing at this ticker.

Director Baskies Arnold M bought 5,000 shares of ANIX at $3.09 on 2024-07-26; stock now -39.2% from 52-week high despite 30-day bounce of +28.7%.

Director Baskies Arnold M purchased 5,000 shares at $3.09, bringing his total holdings to 115,000 shares. This marks his second open-market purchase at Anixa; his prior buy on 2024-03-15 posted a -25.1% return over 90 days, and 0 of his 1 prior buys at this ticker were well-timed. The company is unprofitable with annual revenue declining -59.0%, latest quarterly revenue of $210,000.00, and net income of $-3,139,000.00. The current price of $3.05 sits -39.2% below the 52-week high of $5.02, though the 30-day trend shows +28.7%. This purchase occurs in the context of an unprofitable, revenue-declining biotech operation, and the insider's historical timing at this ticker has not generated positive 90-day returns.